Cargando…

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti–acetylcholine receptor–positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mantegazza, Renato, Wolfe, Gil I., Muppidi, Srikanth, Wiendl, Heinz, Fujita, Kenji P., O'Brien, Fanny L., Booth, Heather D.E., Howard, James F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905790/ https://www.ncbi.nlm.nih.gov/pubmed/33229455 http://dx.doi.org/10.1212/WNL.0000000000011207

Ejemplares similares

Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study
por: Nowak, Richard J., et al.
Publicado: (2020)

Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study
por: Jacob, Saiju, et al.
Publicado: (2020)

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
por: Muppidi, Srikanth, et al.
Publicado: (2019)

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab
por: Vissing, John, et al.
Publicado: (2020)

Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses
por: Howard, James F., et al.
Publicado: (2021)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis
por: Oyama, Munenori, et al.
Publicado: (2020)

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic
por: Jacob, Saiju, et al.
Publicado: (2020)

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
por: Mantegazza, Renato, et al.
Publicado: (2018)

COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
por: Muppidi, Srikanth, et al.
Publicado: (2020)

Refractory generalized myasthenia gravis with myasthenic incomplete ophthalmoplegia successfully treated with eculizumab
por: Weidmayer, Sara L., et al.
Publicado: (2023)

Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
por: Xiao, Hai, et al.
Publicado: (2021)

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
por: Monteleone, Jonathan P. R., et al.
Publicado: (2021)

Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report
por: Vu, Tuan, et al.
Publicado: (2021)

Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis
por: Katyal, Nakul, et al.
Publicado: (2021)

Complement Inhibition for the Treatment of Myasthenia Gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
por: Vélez-Santamaría, Valentina, et al.
Publicado: (2020)

A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
por: Langley, Paul C.
Publicado: (2021)

Current and emerging therapies for the treatment of myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2011)

Animal models of myasthenia gravis: utility and limitations
por: Mantegazza, Renato, et al.
Publicado: (2016)

From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research
por: Mantegazza, Renato, et al.
Publicado: (2020)

Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis
por: Antozzi, Carlo, et al.
Publicado: (2023)

Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
por: Mimori, Masahiro, et al.
Publicado: (2022)

Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis
por: Keller, Christian W., et al.
Publicado: (2021)

Understanding the burden of refractory myasthenia gravis
por: Schneider-Gold, Christiane, et al.
Publicado: (2019)

Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis
por: Harris, Linda, et al.
Publicado: (2019)

Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence
por: Vu, Tuan, et al.
Publicado: (2023)

Utilization of MG‐ADL in myasthenia gravis clinical research and care [Image: see text]
por: Muppidi, Srikanth, et al.
Publicado: (2022)

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis
por: Vu, Tuan, et al.
Publicado: (2023)

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review
por: Waheed, Waqar, et al.
Publicado: (2022)

Clinical Characteristics of Refractory Myasthenia Gravis Patients
por: Suh, Joome, et al.
Publicado: (2013)

Prominent T-Cell Responses against the Acetylcholine Receptor ε Subunit in Myasthenia Gravis
por: Neuhaus, Oliver, et al.
Publicado: (2019)

Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case Series
por: Kang, Seung Ah, et al.
Publicado: (2022)

Safety of an Abbreviated Transition Period When Switching From Intravenous Immunoglobulin to Eculizumab in Patients with Treatment-Refractory Myasthenia Gravis: A Case Series
por: Levine, Todd D.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vdn0a97spoio8215p88j606s4g